Clinical Trial Update: A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) [Phase 2]

View source ↗

Summary

Phase II trial evaluating AZD6094 (HMPL-504) in papillary renal cell carcinoma has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma

Drugs mentioned

• AZD6094 (HMPL-504) (AZD6094)

Snippet

Sponsor: AstraZeneca | Conditions: Papillary Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-10-12